Dalal Suhani, Chitneni Ahish, Berger Amnon A, Orhurhu Vwaire, Dar Bilal, Kramer Bennett, Nguyen Anvinh, Pruit John, Halsted Charles, Kaye Alan D, Hasoon Jamal
A.T. Still University School of Medicine.
Beth Israel Deaconess Medical Center and Harvard Medical School.
Health Psychol Res. 2021 Aug 6;9(1):27241. doi: 10.52965/001c.27241. eCollection 2021.
With the ongoing public health crisis with prescription opioids, there is a need for safer alternatives for medication management in chronic pain patients. Buprenorphine is a partial mu-opioid agonist which is commonly utilized to treat patients with opioid-use disorders. The purpose of this review is to discuss the potential use of this medication for the treatment of chronic pain instead of resorting to more traditional Schedule II opioids. Buprenorphine offers a safer alternative for patients who require opioids to manage chronic pain, given the unique pharmacological properties that allow it to provide adequate analgesia with less abuse potential.
随着当前处方阿片类药物引发的公共卫生危机，慢性疼痛患者需要更安全的药物管理替代方案。丁丙诺啡是一种μ阿片受体部分激动剂，常用于治疗阿片类药物使用障碍患者。本综述的目的是讨论这种药物用于治疗慢性疼痛的潜在用途，而非诉诸更传统的附表二阿片类药物。鉴于丁丙诺啡独特的药理特性使其能够在滥用可能性较小的情况下提供足够的镇痛效果，它为需要阿片类药物来管理慢性疼痛的患者提供了一种更安全的替代方案。
